$TXMD TherapeuticsMD.inc no cure in sight for longs.

Not really a household name among investors but well known to the ever growing of shorts. As of March 26th there was a 38% short interest. Despite FDA approval for 3 new drugs sales have been dismal and the company has increased expenditure on sales to tackle the issue, thus driving operating expenses much higher. The price currently sits at $4.57 well below the analysts average target of $15 which is hard to explain. Like any stock in the drug manufacturing sector the price can spike very quickly, so if your shorting keep stop losses very tight.